IRIS
Bossi, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.441
AS - Asia 9.070
SA - Sud America 1.715
EU - Europa 1.429
Continente sconosciuto - Info sul continente non disponibili 502
AF - Africa 176
OC - Oceania 10
Totale 24.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.948
SG - Singapore 5.672
CN - Cina 1.509
BR - Brasile 1.364
VN - Vietnam 749
IT - Italia 656
HK - Hong Kong 339
CA - Canada 241
GB - Regno Unito 200
IN - India 163
DE - Germania 123
AR - Argentina 122
MX - Messico 118
BD - Bangladesh 112
FR - Francia 76
ID - Indonesia 61
ZA - Sudafrica 61
EC - Ecuador 60
TR - Turchia 60
ES - Italia 57
CO - Colombia 49
IQ - Iraq 46
PL - Polonia 43
VE - Venezuela 41
JP - Giappone 40
RU - Federazione Russa 38
NL - Olanda 34
UA - Ucraina 34
MY - Malesia 33
PK - Pakistan 32
UZ - Uzbekistan 30
MA - Marocco 28
CL - Cile 26
CR - Costa Rica 25
SA - Arabia Saudita 25
JM - Giamaica 24
NP - Nepal 24
SE - Svezia 23
KE - Kenya 21
PH - Filippine 21
TN - Tunisia 20
AE - Emirati Arabi Uniti 19
PY - Paraguay 19
JO - Giordania 18
FI - Finlandia 15
IE - Irlanda 15
HN - Honduras 14
TT - Trinidad e Tobago 14
UY - Uruguay 14
EG - Egitto 13
SV - El Salvador 13
TH - Thailandia 13
AT - Austria 11
LT - Lituania 11
BE - Belgio 10
EE - Estonia 10
IR - Iran 10
KZ - Kazakistan 10
PE - Perù 10
IL - Israele 9
TW - Taiwan 9
BA - Bosnia-Erzegovina 8
CH - Svizzera 8
OM - Oman 8
AL - Albania 7
AM - Armenia 7
AU - Australia 7
ET - Etiopia 7
KR - Corea 7
NI - Nicaragua 7
PR - Porto Rico 7
PT - Portogallo 7
CY - Cipro 6
DZ - Algeria 6
RO - Romania 6
RS - Serbia 6
BB - Barbados 5
BY - Bielorussia 5
GE - Georgia 5
HR - Croazia 5
AZ - Azerbaigian 4
BH - Bahrain 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
HU - Ungheria 4
LB - Libano 4
PS - Palestinian Territory 4
SN - Senegal 4
BG - Bulgaria 3
CI - Costa d'Avorio 3
GD - Grenada 3
GY - Guiana 3
KH - Cambogia 3
NG - Nigeria 3
PA - Panama 3
QA - Qatar 3
SR - Suriname 3
Totale 23.800
Salva come PNG Salva come JPEG
Città #
Singapore 2.313
San Jose 1.961
Ashburn 1.387
The Dalles 920
Dallas 606
Council Bluffs 540
Shanghai 538
Santa Clara 406
Beijing 386
Hong Kong 315
Ho Chi Minh City 288
Los Angeles 266
New York 212
Milan 210
Hanoi 164
Buffalo 151
São Paulo 114
Seattle 99
Atlanta 77
Chicago 76
Phoenix 74
Rome 73
North Bergen 63
Assago 62
Montreal 58
Orem 52
Brooklyn 50
Houston 47
Mexico City 46
Charlotte 45
Toronto 44
Naples 43
San Francisco 43
Johannesburg 42
Boardman 38
Rio de Janeiro 38
Warsaw 37
Curitiba 34
Denver 34
Munich 34
Philadelphia 32
Da Nang 31
Tokyo 31
Brasília 29
Tashkent 29
Boston 28
Haiphong 28
London 27
Campinas 26
Frankfurt am Main 25
Princeton 25
Belo Horizonte 24
Chennai 24
Manchester 23
Las Vegas 22
Queens 22
Stockholm 21
Abbeville 19
Guayaquil 19
Quito 19
Secaucus 19
Amsterdam 18
Cleveland 18
Mumbai 18
Nairobi 18
New Delhi 18
Pittsburgh 18
Ribeirão Preto 18
Kuala Lumpur 17
Miami 17
Milwaukee 17
The Bronx 17
Wilmington 17
Bogotá 16
Columbus 16
Dhaka 16
Paris 16
Baghdad 15
Figino 15
Istanbul 15
Newark 15
San José 15
Santiago 15
Turin 15
Detroit 14
Jacksonville 14
Kingston 14
Pasadena 14
Poplar 14
Amman 13
Biên Hòa 13
Bologna 13
Goiânia 13
Louisville 13
San Salvador 13
Tunis 13
Vancouver 13
Ankara 12
Birmingham 12
Buenos Aires 12
Totale 13.099
Salva come PNG Salva come JPEG
Nome #
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents 260
New trends in supportive care of head and neck cancers 129
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis 126
Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis 119
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer 116
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 111
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 109
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 109
The present and the future of benzydamine: expert opinion paper 104
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines 104
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 102
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 101
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents 101
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 99
A case of otoliquorrhoea secondary to immunotherapy response in head and neck cutaneous squamous cell carcinoma. When abrupt response may worry the physician 96
Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study 96
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck 94
Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel 92
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial 88
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 88
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 87
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy 87
The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing 85
A ct-based radiomic signature can be prognostic for 10-months overall survival in metastatic tumors treated with nivolumab: An exploratory study 85
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 83
A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer 82
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab 81
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 80
International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma 79
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 77
Role of Radiotherapy in the management of metastases from salivary gland carcinoma. 77
Dietary intake effects on severity of cancer treatment‐induced mucositis: A cross‐sectional study 75
Computer Vision Foundation Models in Endoscopy: Proof of Concept in Oropharyngeal Cancer 75
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area 74
M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy ± systemic therapy – A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 73
Editorial: Understanding and treating rare nasal and paranasal sinus cancers 72
USO DI MIRNA COME BIOMARCATORI PER LA DIAGNOSI E PROGNOSI DEL CARCINOMA ORALE A CELLULE SQUAMOSE 72
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 72
International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Interdisciplinary Modified Delphi Study 72
Financial toxicity questionnaire (FIT): development and validation of the italian version (FITALY) in head and neck cancer patients undergoing multimodal curative treatment 71
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort 71
Phase IV study on the use of benzydamine mouthwash in radiation-induced oral mucositis in patients with head and neck cancer 71
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients 70
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group 69
The Use of Artificial Intelligence in Head and Neck Cancers: A Multidisciplinary Survey 69
Italian version of the M.D. Anderson Symptom Inventory—Head and Neck Module: linguistic validation 69
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 68
Regionally advanced nasopharyingeal carcinoma: Long-term outcome after sequential chemotherapy and radiotherapy 68
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 68
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma 68
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of Aqualief™ mucoadhesive tablets in head and neck cancer patients who developed radiation-induced xerostomia 68
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines 67
Not all hematopoietic growth factors are created equal: Should we gain information for their use with immunotherapy? 67
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma 67
Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis 66
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports 66
A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes 66
Overview of oral potentially malignant disorders: From risk factors to specific therapies 65
Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations 65
ESMO Guidelines: Cancer patient management during the COVID-19 pandemic 65
A European survey on the practice of nutritional interventions in head–neck cancer patients undergoing curative treatment with radio(chemo)therapy 64
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma 64
Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 64
Functional profiles of curatively treated adenoid cystic carcinoma unveil prognostic features and potentially targetable pathways 63
A complete remission with androgen-deprivation therapy in a recurrent androgen recptor-expressing adenocarcinoma of the parotid gland [1] 63
Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework 63
Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study) 63
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial 63
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 63
Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area 62
Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma 62
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting 62
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 62
Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? 62
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 61
A NATURAL HISTORY OF A SERIES OF RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC) 61
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis 61
Peripherally or centrally inserted central catheters: what is the best vascular access device for cancer patients? 61
The use of fentanyl in pain management in head and neck cancer patients: a narrative review 61
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients 61
Role of TORS as De-Escalation Strategy in HPV-Related Oropharyngeal Cancer, What We Need to Know 60
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 60
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus 60
New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma 60
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target? 60
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 60
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic 60
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy 60
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines 60
Nodal status in major salivary gland cancer: External validation of a novel N- classification 60
Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT) 60
Regional disease in head and neck cutaneous squamous cell carcinoma: the role of primary tumor characteristics and number of nodal metastases 59
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy 59
Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety 59
Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods 59
Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations 59
The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity 59
New insights in chemotherapy 59
FURTHER IMPROVEMENT IN OUTCOMES OF NASOPHARYNGEAL CARCINOMA WITH OPTIMIZED RADIOTHERAPY AND INDUCTION PLUS CONCOMITANT CHEMOTHERAPY: AN UPDATE OF THE MILAN EXPERIENCE 58
Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer 58
Totale 7.591
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 2 0 0 0 1 0 0 1 0
2022/202334 4 0 2 4 5 3 0 1 11 2 1 1
2023/20241.254 2 2 6 0 0 0 1 434 43 53 251 462
2024/20254.244 138 26 56 86 45 395 214 189 825 1.141 533 596
2025/202613.643 1.797 902 705 992 466 739 3.790 616 681 988 799 1.168
2026/20275.154 818 883 2.441 1.012 0 0 0 0 0 0 0 0
Totale 24.343